

118TH CONGRESS
2D SESSION

H. R. 7164

To advance population research for chronic pain.

IN THE HOUSE OF REPRESENTATIVES

JANUARY 31, 2024

Ms. CARAVEO (for herself and Mr. NUNN of Iowa) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To advance population research for chronic pain.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Advancing Research
5 for Chronic Pain Act of 2024”.

6 **SEC. 2. NATIONAL CHRONIC PAIN INFORMATION SYSTEM.**

7 Part P of title III of the Public Health Service Act
8 (42 U.S.C. 280g et seq.) is amended by adding at the end
9 the following:

10 **“SEC. 399V–8. CHRONIC PAIN RESEARCH.**

11 “(a) IN GENERAL.—The Secretary, in consultation
12 with the Director of the Centers for Disease Control and

1 Prevention, the Director of the National Institutes of
2 Health, and the heads of other agencies as the Secretary
3 determines appropriate, shall—

4 “(1) utilize available Federal research data to
5 clarify the incidence and prevalence of chronic pain
6 from any source, including injuries, operations, and
7 diseases and conditions;

8 “(2) identify gaps in the available research data
9 and collect deidentified population research data
10 using medical claims and survey data to fill gaps in
11 available research data, such as information con-
12 cerning—

13 “(A) incidence and prevalence of specific
14 pain conditions;

15 “(B) demographics and other information,
16 such as age, race, ethnicity, gender, and geo-
17 graphic location;

18 “(C) the incidence and prevalence of
19 known chronic pain conditions, as well as of
20 diseases and conditions that include or lead to
21 pain;

22 “(D) risk factors that may be associated
23 with chronic pain conditions, such as genetic
24 and environmental risk factors and other infor-
25 mation, as appropriate;

1 “(E) diagnosis and progression markers;

2 “(F) both direct and indirect costs of ill-

3 ness;

4 “(G) the epidemiology of the conditions;

5 “(H) the detection, management, and

6 treatment of the conditions;

7 “(I) the epidemiology, detection, manage-

8 ment, and treatment of frequent secondary or

9 co-occurring conditions, such as depressive, anx-

10 iety, and substance use disorders;

11 “(J) the utilization of medical and social

12 services by patients with chronic pain condi-

13 tions, including the direct health care costs of

14 pain treatment, both traditional and alternative,

15 and the indirect costs (such as missed work,

16 public and private disability, and reduction in

17 productivity); and

18 “(K) the effectiveness of evidence-based

19 treatment approaches on chronic pain condi-

20 tions;

21 “(3) develop, in collaboration with individuals

22 and organizations with appropriate chronic pain ex-

23 pertise, including patients or patient advocates, epi-

24 demiologists, representatives of national voluntary

25 health associations, health information technology

1 experts, clinicians, and research scientists, standard
2 definitions and approaches for population research
3 on chronic pain to efficiently promote greater com-
4 parability of data; and

5 “(4) disseminate, pursuant to the public
6 webpage under subsection (b), and, as appropriate,
7 to the public and to other Federal departments and
8 agencies, any findings, developed population research
9 standards, and available Federal data sources re-
10 lated to chronic pain.

11 “(b) DISSEMINATION.—The Secretary, acting
12 through the Director of the Centers for Disease Control
13 and Prevention, shall establish a public webpage, to be
14 known as the Chronic Pain Information Hub, that—

15 “(1) aggregates and summarizes available Fed-
16 eral data sources, indicators, and peer-reviewed re-
17 search related to chronic pain;

18 “(2) includes an up-to-date summary of com-
19 plete, underway, and planned data collection and
20 analysis related to chronic pain that is conducted
21 and supported by the Centers for Disease Control
22 and Prevention; and

23 “(3) translates research findings into clinical
24 tools and resources, recommendations for closing re-
25 search gaps, and recommendations for population re-

1 search standards for researchers, with recommenda-
2 tions updated annually to incorporate research find-
3 ings from the prior year.

4 “(c) CONFLICTS OF INTEREST.—If an individual or
5 organization that collaborates with the Secretary in car-
6 rying out subsection (a) receives a payment or other trans-
7 fer of value of a type described in section
8 1128G(a)(1)(A)(vi) of the Social Security Act from a man-
9 ufacturer of a drug (including a biological product) or de-
10 vice that would be required to be disclosed pursuant to
11 section 1128G(a)(1) of the Social Security Act, if the indi-
12 vidual or organization were a covered recipient or if such
13 disclosure were required upon request of or by designation
14 on behalf of a covered recipient pursuant to such section,
15 the individual or organization shall disclose to the Sec-
16 retary information regarding such payment or other trans-
17 fer of value. The Secretary shall make such disclosures
18 publicly available.

19 “(d) REPORT.—Not later than 2 years after the date
20 of the enactment of the Advancing Research for Chronic
21 Pain Act of 2024, the Secretary shall submit a report to
22 Congress concerning the implementation of this section.

23 Such report shall include information on—

24 “(1) the development and maintenance of the
25 Chronic Pain Information Hub;

1 “(2) the information made available through
2 the Chronic Pain Information Hub;

3 “(3) the data gaps identified, and planned ef-
4 forts to address such gaps;

5 “(4) the process established for soliciting feed-
6 back from collaborators; and

7 “(5) feedback received from collaborators.

8 “(e) DEFINITION.—In this section, the term ‘chronic
9 pain’ means persistent or recurrent pain lasting longer
10 than 3 months.

11 “(f) AUTHORIZATION OF APPROPRIATIONS.—To
12 carry out this section, there is authorized to be appro-
13 priated such sums as may be necessary for each of fiscal
14 years 2024 through 2028.”.

